Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has ...

Relay Therapeutics, Inc.’s RLAY share price has surged by 5.63%, which has investors questioning if this is right time to sell.

HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:?HCM; HKEX:?13) today announces that it has completed enrollment of the registration phase of its Phase II trial of savolitinib in gastric cancer ...

Zai Lab's repotrectinib label expansion accepted in China for treating advanced solid tumors with NTRK gene fusion.

Dizal will also present results from the ongoing Phase I/II study of DZD6008, a 4th generation EGFR TKI with full BBB penetration, in advanced EGFR mutation positive (EGFRm) non-small cell lung cancer ...

Bicycle Therapeutics targets innovative cancer treatments with potential, like zelenectide pevedotin. Read here for an ...

Zai Lab Limited (NASDAQ: ZLAB) shares barely moved Monday, on word China’s National Medical Products Administration (NMPA) has accepted the supplemental New Drug Application (sNDA) for repotrectinib ...

Nuvalent Inc. has identified proto-oncogene tyrosine-protein kinase ROS (ROS1; MCF3) and/or ALK tyrosine kinase receptor inhibitors reported to be useful for the treatment of cancer.

Zai Lab (ZLAB) announced that China’s National Medical Products Administration has accepted the supplemental new drug application for ...

A recent publication in Genes & Diseases has delivered a compelling synthesis of the latest insights into the cellular ...

We recently published a list of the 11 Most Promising Penny Stocks According to Analysts. In this article, we are going to ...

The team is optimizing the cancer genome analysis system to integrate it into CRC diagnosis and tailor treatments based on ...